Previous 10 | Next 10 |
home / stock / bovnf / bovnf news
LUND, SWEDEN / ACCESSWIRE / April 6, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today a...
LUND, SWEDEN / ACCESSWIRE / March 13, 2023 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today informed its shareholders that BioI...
BioInvent International press release ( OTCPK:BOVNF ): Q4 GAAP EPS of -SEK1.21. Revenue of SEK20.6M (+320.4% Y/Y). For further details see: BioInvent International GAAP EPS of -SEK1.21, revenue of SEK20.6M
LUND, SWEDEN / ACCESSWIRE / February 22, 2023 / BioInvent International (STO:BINV) "BioInvent made significant advances in 2022, further developing our exciting pipeline of novel and first-in-class immuno-modulatory antibodies for cancer therapy and substantially reinforcing the company's fina...
LUND, SWEDEN / ACCESSWIRE / February 21, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors and analysts to a presentation of the Year-end report 2022 at 2:00 pm CET on February 22. The report will be published at 8:00 ...
LUND, SE / ACCESSWIRE / January 31, 2023 / BioInvent International (STO:BINV) Lund, Sweden, January 31, 2023 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per January 31, 2023 amounts to 65,804,362 shares, corr...
Strategic equity investment of USD 3 million to support clinical advancement of BI-1206 in Non-Hodgkin's Lymphoma Supports also clinical development of BI-1808 in cutaneous T-cell lymphoma LLS TAP is a strategic funding initiative to accelerate innovative blood cancer therapeutics ...
Summary Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment. Nanjing Frontier Biotechnologies completed a $29 million private placemen...
BioInvent International ( OTCPK:BOVNF ) said it completed the dose escalation part of a phase 1/2a trial of BI-1808 in patients with certain types of cancers. The phase 1/2a study is evaluating the safety and potential efficacy of BI-1808 as a single agent and in combination...
BioInvent International press release ( OTCPK:BOVNF ): Q2 GAAP EPS of SEK 2.86. Revenue of SEK 270.9M (+5011.3% Y/Y). Cash flow from operating activities -SEK62.5M vs. -SEK63.1M Y/Y. For further details see: BioInvent International GAAP EPS of...
News, Short Squeeze, Breakout and More Instantly...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...
LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China Nat...
BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development...